Condition: Prostate Cancer Patients Treated by Radiotherapy · Prostate Cancer (Adenocarcinoma) · Sponsor: Candel Therapeutics, Inc.
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Academic Urology and Urogynecology of Arizona | Peoria, Arizona, United States | Recruiting |
| Colorado Clinical Research | Lakewood, Colorado, United States | Recruiting |
| Urology Associates | Littleton, Colorado, United States | Recruiting |
| Chesapeake Urology Research Associates | Towson, Maryland, United States | Recruiting |
| Sheldon Freedman, MD Ltd. | Las Vegas, Nevada, United States | Recruiting |
| Summit Health | Saddle Brook, New Jersey, United States | Recruiting |
| START Carolinas | Myrtle Beach, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07332000